Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > FDA: Multaq Not Safe in Subgroup of AF Patients

Drug Industry Daily

Dec. 20, 2011 | Vol. 8 No. 247

FDA: Multaq Not Safe in Subgroup of AF Patients

The FDA is requiring a boxed warning for Sanofi-Aventis’ atrial fibrillation (AF) treatment Multaq in patients with permanent AF after a safety review showed a higher risk of cardiovascular (CV) death.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

Lawmakers Say Gluten Should Be Noted On Drug Labels FDA to Focus on HIV in Next Patient-Focused Drug Development Meeting Report Pokes Holes In FDA Celexa Dose Warning FDA Advisers Fret Aveed; Support GSK’s COPD Drug

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.